P3 Health Partners (NASDAQ:PIII) Announces Quarterly Earnings Results, Beats Estimates By $5.17 EPS

P3 Health Partners (NASDAQ:PIII) posted its quarterly earnings results on Thursday. The company reported $0.32 EPS for the quarter, beating the consensus estimate of ($4.85) by $5.17, FiscalAI reports. P3 Health Partners had a negative net margin of 8.57% and a negative return on equity of 302.33%. The firm had revenue of $386.39 million for the quarter, compared to analyst estimates of $391.45 million.

Here are the key takeaways from P3 Health Partners’ conference call:

• P3 reported $26 million of adjusted EBITDA in Q1, well above internal expectations, and raised its full-year 2026 outlook to $20 million-$60 million as execution improved.
• The company said its Medicare Advantage medical cost trend was roughly flat versus the full-year 2025 baseline, which it framed as a meaningful differentiator versus peers guiding to 7%+ trend.
• Management highlighted stronger payer economics, including about a 15% year-over-year improvement in MA funding rates and delegated functions covering 63% of membership in 2026.
• The company said its balance sheet improved after roughly $250 million of debt was converted to preferred equity, and it believes it now exceeds the Nasdaq minimum stockholders’ equity requirement.
• Membership declined year over year to about 106,000 at-risk lives as P3 exited lower-economics arrangements, but total lives under management reached about 135,000 including service arrangements and a new Nebraska partnership.

P3 Health Partners Price Performance

Shares of NASDAQ:PIII traded up $7.26 during midday trading on Friday, reaching $11.29. The company had a trading volume of 65,159,971 shares, compared to its average volume of 134,546. The stock’s fifty day moving average price is $3.05 and its 200-day moving average price is $3.85. The stock has a market capitalization of $81.43 million, a P/E ratio of -0.29 and a beta of 0.48. P3 Health Partners has a one year low of $1.52 and a one year high of $14.35.

Trending Headlines about P3 Health Partners

Here are the key news stories impacting P3 Health Partners this week:

• Positive Sentiment: P3 Health Partners reported Q1 2026 earnings of $0.32 per share, beating expectations for a large loss, which appears to be the main catalyst behind the stock’s surge. P3 Health Partners (PIII) Stock Surges Over 42% After Hours: Here’s Why
• Positive Sentiment: The company’s revenue for the quarter was $386.39 million, roughly in line with estimates, helping support investor confidence that operating results were better than expected overall. P3 Health Partners earnings press release
• Neutral Sentiment: Trading in PIII was halted several times for LULD pauses, indicating extreme volatility and a fast-moving price reaction to the earnings news.
• Neutral Sentiment: Commentary following the report highlighted that the stock was reacting to a narrower-than-expected loss and a sharp after-hours move, underscoring speculation and momentum trading rather than a fresh business announcement. P3 Health Partners (PIII) stock surges over 42% after hours: Here’s why
• Negative Sentiment: Despite the earnings beat, P3 Health Partners still reported a negative net margin and negative return on equity, so the underlying turnaround story remains unproven.

Analyst Ratings Changes

Several research firms recently commented on PIII. Weiss Ratings restated a “sell (e+)” rating on shares of P3 Health Partners in a report on Tuesday, April 21st. Lake Street Capital restated a “buy” rating and issued a $14.00 price target (up from $4.00) on shares of P3 Health Partners in a report on Friday. TD Cowen cut their price target on shares of P3 Health Partners from $8.00 to $3.00 and set a “hold” rating on the stock in a report on Thursday, April 2nd. Finally, UBS Group set a $14.00 price target on shares of P3 Health Partners in a report on Friday. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.33.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.